CELG up +1.47% percent Today $CELG High is at 108.
Post# of 119
Posted On: 11/10/2014 1:24:14 PM
CELG up +1.47% percent Today $CELG High is at 108.25 and the Low 106.00 with current volume of 1,576,701.
Recent News posted below.
Celgene Corp CELG other info.
http://investorshangout.com/Celgene-Corporation-CELG-53644/
CELG Celgene Corp Recent Headline News
Celgene Earnings Hindsight: Up 6.0% in Last 18 Days (CELG)
Comtex SmarTrend(R) - 23 mins ago
Two weeks ago on October 23rd, 2014 Celgene (NASDAQ:CELG) reported earnings and analysts, on average, expected earnings of $0.95 on sales of $2.0 billion. Celgene actually reported earnings of $0.97 per share on sales of $2.0 billion, beating EPS estimates by $0.02 and beating revenue estimates by $25.8 million. Shares of Celgene have climbed from $100.40 to $106.45, representing a gain of 6.0% since the company reported earnings 18 days ago.
CELG: 107.75 (+1.30)
Early Glance: Biotechnology companies
AP - 2 hrs 55 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.49 (+1.04), AMGN: 162.26 (+2.01), CELG: 107.75 (+1.30)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.91 (-0.05), ACT: 246.11 (+0.20), JAZZ: 172.53 (+1.73), UNH: 94.52 (+0.91), CELG: 107.75 (+1.30), CELGZ: 3.17 (-0.07)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 109.22 (-3.55), JNJ: 108.54 (+0.34), BIIB: 325.72 (+4.97), PTLA: 27.44 (+0.05), GILD: 107.49 (+1.04), CELG: 107.75 (+1.30)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 107.49 (+1.04), AMGN: 162.26 (+2.01), CELG: 107.75 (+1.30)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 195.21 (-0.79), HCA: 67.31 (+1.56), BIDU: 246.32 (+9.78), ZBRA: 72.82 (+0.23), SWKS: 60.97 (+1.09), ALK: 56.01 (+0.87), CELG: 107.75 (+1.30)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.54 (+0.34), PCYC: 133.35 (-0.14), GILD: 107.49 (+1.04), AZN: 73.24 (+0.36), GSK: 45.17 (+0.26), BMY: 58.57 (+0.25), CELG: 107.75 (+1.30)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 107.49 (+1.04), AMGN: 162.26 (+2.01), CELG: 107.74 (+1.29)
Data from More Than 160 Abstracts Highlighting Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)
Business Wire - Thu Nov 06, 4:30PM CST
Celgene Corporation (NASDAQ:CELG) today announced that data from more than 160 abstracts, including 39 oral presentations, evaluating Celgene investigational products and investigational uses of marketed products will be presented at the 56th American Society of Hematology Annual Meeting between Dec. 6-9 in San Francisco, Calif.
CELG: 107.74 (+1.29), CELGZ: 3.17 (-0.07)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.52 (+1.46), RNA: 11.90 (-0.24), AGIO: 79.27 (+7.21), CELG: 107.74 (+1.29)
Why Celgene Corporation Stock Rocketed 13% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:07AM CST
CELG data by YCharts What: Shares of biopharmaceutical giant Celgene rocketed higher by 13% in October, based on data provided by S&P Capital IQ , after the company reported better-than-expected third-quarter earnings results and...
CELG: 107.74 (+1.29)
Uptrend Call Working As Celgene Stock Rises 11.2% (CELG)
Comtex SmarTrend(R) - Wed Nov 05, 5:19PM CST
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on October 21st, 2014 at $94.56. In approximately 2 weeks, Celgene has returned 11.20% as of today's recent price of $105.15.
CELG: 107.74 (+1.29)
Let Major Indexes Dictate Buy, Sell Decisions
at Investor's Business Daily - Wed Nov 05, 5:01PM CST
The S&P 500 and Nasdaq composite serve as guideposts to the market's health. Ignore them at your own peril. Every day, IBD analyzes the action of these major stock averages to determine whether the market is in an uptrend (healthy) or a correction...
LCI: 51.18 (+1.01), AKRX: 35.26 (-1.33), ORLY: 179.30 (+0.30), AFSI: 50.36 (+0.47), CELG: 107.74 (+1.29)
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver
PR Newswire - Wed Nov 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BABA, BLMN, VJET, JOBS and CELG.
JOBS: 34.57 (+0.51), VJET: 12.36 (+0.03), BLMN: 21.69 (unch), CELG: 107.74 (+1.29), BABA: 117.30 (+2.74)
5 Things Celgene Corporation's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 6:51AM CST
Source: U.S. Department of Agriculture via Flickr . Following another successful quarterly report, investors and shareholders of Celgene have to be wondering if anything can stop this stock from heading higher . For the quarter, Celgene...
OMED: 20.03 (-0.16), AMGN: 162.26 (+2.01), ABBV: 63.50 (+2.00), CELG: 107.74 (+1.29)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.21 (-0.79), BIIB: 325.72 (+4.97), VRX: 127.65 (+1.54), ACT: 246.11 (+0.20), JAZZ: 172.53 (+1.73), ALXN: 194.23 (+0.42), CELG: 107.74 (+1.29)
Recent News posted below.
Celgene Corp CELG other info.
http://investorshangout.com/Celgene-Corporation-CELG-53644/
CELG Celgene Corp Recent Headline News
Celgene Earnings Hindsight: Up 6.0% in Last 18 Days (CELG)
Comtex SmarTrend(R) - 23 mins ago
Two weeks ago on October 23rd, 2014 Celgene (NASDAQ:CELG) reported earnings and analysts, on average, expected earnings of $0.95 on sales of $2.0 billion. Celgene actually reported earnings of $0.97 per share on sales of $2.0 billion, beating EPS estimates by $0.02 and beating revenue estimates by $25.8 million. Shares of Celgene have climbed from $100.40 to $106.45, representing a gain of 6.0% since the company reported earnings 18 days ago.
CELG: 107.75 (+1.30)
Early Glance: Biotechnology companies
AP - 2 hrs 55 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.49 (+1.04), AMGN: 162.26 (+2.01), CELG: 107.75 (+1.30)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.91 (-0.05), ACT: 246.11 (+0.20), JAZZ: 172.53 (+1.73), UNH: 94.52 (+0.91), CELG: 107.75 (+1.30), CELGZ: 3.17 (-0.07)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 109.22 (-3.55), JNJ: 108.54 (+0.34), BIIB: 325.72 (+4.97), PTLA: 27.44 (+0.05), GILD: 107.49 (+1.04), CELG: 107.75 (+1.30)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 107.49 (+1.04), AMGN: 162.26 (+2.01), CELG: 107.75 (+1.30)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 195.21 (-0.79), HCA: 67.31 (+1.56), BIDU: 246.32 (+9.78), ZBRA: 72.82 (+0.23), SWKS: 60.97 (+1.09), ALK: 56.01 (+0.87), CELG: 107.75 (+1.30)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.54 (+0.34), PCYC: 133.35 (-0.14), GILD: 107.49 (+1.04), AZN: 73.24 (+0.36), GSK: 45.17 (+0.26), BMY: 58.57 (+0.25), CELG: 107.75 (+1.30)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 107.49 (+1.04), AMGN: 162.26 (+2.01), CELG: 107.74 (+1.29)
Data from More Than 160 Abstracts Highlighting Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)
Business Wire - Thu Nov 06, 4:30PM CST
Celgene Corporation (NASDAQ:CELG) today announced that data from more than 160 abstracts, including 39 oral presentations, evaluating Celgene investigational products and investigational uses of marketed products will be presented at the 56th American Society of Hematology Annual Meeting between Dec. 6-9 in San Francisco, Calif.
CELG: 107.74 (+1.29), CELGZ: 3.17 (-0.07)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.52 (+1.46), RNA: 11.90 (-0.24), AGIO: 79.27 (+7.21), CELG: 107.74 (+1.29)
Why Celgene Corporation Stock Rocketed 13% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:07AM CST
CELG data by YCharts What: Shares of biopharmaceutical giant Celgene rocketed higher by 13% in October, based on data provided by S&P Capital IQ , after the company reported better-than-expected third-quarter earnings results and...
CELG: 107.74 (+1.29)
Uptrend Call Working As Celgene Stock Rises 11.2% (CELG)
Comtex SmarTrend(R) - Wed Nov 05, 5:19PM CST
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on October 21st, 2014 at $94.56. In approximately 2 weeks, Celgene has returned 11.20% as of today's recent price of $105.15.
CELG: 107.74 (+1.29)
Let Major Indexes Dictate Buy, Sell Decisions
at Investor's Business Daily - Wed Nov 05, 5:01PM CST
The S&P 500 and Nasdaq composite serve as guideposts to the market's health. Ignore them at your own peril. Every day, IBD analyzes the action of these major stock averages to determine whether the market is in an uptrend (healthy) or a correction...
LCI: 51.18 (+1.01), AKRX: 35.26 (-1.33), ORLY: 179.30 (+0.30), AFSI: 50.36 (+0.47), CELG: 107.74 (+1.29)
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver
PR Newswire - Wed Nov 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BABA, BLMN, VJET, JOBS and CELG.
JOBS: 34.57 (+0.51), VJET: 12.36 (+0.03), BLMN: 21.69 (unch), CELG: 107.74 (+1.29), BABA: 117.30 (+2.74)
5 Things Celgene Corporation's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 6:51AM CST
Source: U.S. Department of Agriculture via Flickr . Following another successful quarterly report, investors and shareholders of Celgene have to be wondering if anything can stop this stock from heading higher . For the quarter, Celgene...
OMED: 20.03 (-0.16), AMGN: 162.26 (+2.01), ABBV: 63.50 (+2.00), CELG: 107.74 (+1.29)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.21 (-0.79), BIIB: 325.72 (+4.97), VRX: 127.65 (+1.54), ACT: 246.11 (+0.20), JAZZ: 172.53 (+1.73), ALXN: 194.23 (+0.42), CELG: 107.74 (+1.29)
(0)
(0)Celgene Corporation (CELG) Stock Research Links
Scroll down for more posts ▼